ReviewTherapeutics and clinical risk management2020
The Double Burden of the COVID-19 Pandemic and Polypharmacy on Geriatric Population - Public Health Implications.
Review in Therapeutics and clinical risk management, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 48 citations in OpenAlex.
- Trends in respiratory failure mortality in the United States from 1999 to 2023.Frontiers in medicine · 2026Article
- The Role of Health-Related Factors in the Prevalence and Severity of COVID-19: A Retrospective Cohort Study Based on Sabzevar Persian Cohort Data.Health science reports · 2026Article
- Emotional Experiences of the Home-Dwelling Older Adults During the Isolation of the Coronavirus Disease 2019 Pandemic: A Qualitative Systematic Review.Health science reports · 2025Review
- Prognostic Accuracy of Nutritional Assessment Tools in Critically-Ill COVID-19 Patients.Journal of clinical medicine · 2025Article
- Association of Polypharmacy and Burden of Comorbidities on COVID-19 Adverse Outcomes in People with Type 1 or Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Development Of the VAMPCT Score for Predicting Mortality in CKD Patients with COVID-19.International journal of medical sciences · 2025Article
- Article
- Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice.European cardiology · 2024Review
- Comparative analysis of the safety and effectiveness of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19: a retrospective study from a tertiary hospital in China.Frontiers in pharmacology · 2024Article
- Article
- [Factors associated with the risk of hospitalization and death related to SARS-CoV-2 infection.]Revista espanola de salud publica · 2023Article
- Managing dementia care during COVID-19 pandemic: caregivers' experiences in Odisha, India.Primary health care research & development · 2023Article
- Article
- The Point-of-Care Ultrasound (POCUS) by the Handheld Ultrasound Devices (HUDs) in the COVID-19 Scenario: a Review of the Literature.SN comprehensive clinical medicine · 2023Review
- A Bibliometric Analysis of COVID-19 Scientific Literature From the English-Speaking Caribbean.Cureus · 2022Review
- Multimorbidity and Polytherapy in Patients with Femoral Neck Fracture: A Retrospective Observational Study.Journal of clinical medicine · 2022Article
- The National Programme for Health Care of the Elderly: A Review of its Achievements and Challenges in India.Annals of geriatric medicine and research · 2022Article
- Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies.Tropical medicine and health · 2022Article
- Potential for Drug Interactions and Polypharmacy From Treatment of COVID-19 in Long-Term Care.Journal of the American Medical Directors Association · 2022Article
- Belongingness challenged: Exploring the impact on older adults during the COVID-19 pandemic.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 pandemic is inducing acute respiratory distress syndrome, multi-organ failure, and eventual death. Respiratory failure is the leading cause of mortality in the elderly population with pre-existing medical conditions. This group is particularly vulnerable to infections due to a declined immune system, comorbidities, geriatric syndrome, and potentially inappropriate polypharmacy. These conditions make the elderly population more susceptible to the harmful effects of medications and the deleterious consequences of infections, including MERS-CoV, SARS-CoV, and SARS-CoV-2. Chronic diseases among elderlies, including respiratory diseases, hypertension, diabetes, and coronary heart diseases, present a significant challenge for healthcare professionals. To comply with the clinical guidelines, the practitioner may prescribe a complex medication regimen that adds up to the burden of pre-existing treatment, potentially inducing adverse drug reactions and leading to harmful side-effects. Consequently, the geriatric population is at increased risk of falls, frailty, and dependence that enhances their susceptibility to morbidity and mortality due to SARS-CoV-2 respiratory syndrome, particularly interstitial pneumonia. The major challenge resides in the detection of infection that may present as atypical manifestations in this age group. Healthy aging can be possible with adequate preventive measures and appropriate medication regimen and follow-up. Adherence to the guidelines and recommendations of WHO, CDC, and other national/regional/international agencies can reduce the risks of SARS-CoV-2 infection. Better training programs are needed to enhance the skill of health care professionals and patient's caregivers. This review explains the public health implications associated with polypharmacy on the geriatric population with pre-existing co-morbidities during the COVID-19 pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.